{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:54:05Z","timestamp":1791525245386,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Bristol-Myers Squibb"],"award-info":[{"award-number":["Bristol-Myers Squibb"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00520-020-05493-y","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T03:27:23Z","timestamp":1589167643000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Symptom burden and its functional impact in patients with \u201csymptomatic\u201d relapsed or refractory multiple myeloma"],"prefix":"10.1007","volume":"29","author":[{"given":"Mona","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa M.","family":"Zyczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Garcia-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"issue":"8","key":"5493_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/jco.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK (2018) Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36(8):728\u2013734. https:\/\/doi.org\/10.1200\/jco.2017.76.5032","journal-title":"J Clin Oncol"},{"issue":"5","key":"5493_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5):2521\u20132526. https:\/\/doi.org\/10.1182\/blood-2007-08-104984","journal-title":"Blood"},{"issue":"1","key":"5493_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K (2016) Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin 32(1):95\u2013103. https:\/\/doi.org\/10.1185\/03007995.2015.1105202","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"5493_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag 46(5):671\u2013680. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.11.003","journal-title":"J Pain Symptom Manag"},{"key":"5493_CR5","unstructured":"NCCN (2019) Clinical practice guidelines-multiple myeloma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed 10 Oct 2019"},{"issue":"7","key":"5493_CR6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano F, Cavo M, Niscola P, Caravita T, Efficace F (2018) Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review. Support Care Cancer 26(7):2075\u20132090. https:\/\/doi.org\/10.1007\/s00520-018-4137-x","journal-title":"Support Care Cancer"},{"issue":"4","key":"5493_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89(4):311\u2013319. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"5493_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","volume":"83","author":"AK Kvam","year":"2009","unstructured":"Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009) Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83(4):279\u2013289. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01303.x","journal-title":"Eur J Haematol"},{"issue":"12","key":"5493_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/sim.4780101207","volume":"10","author":"M Schumacher","year":"1991","unstructured":"Schumacher M, Olschewski M, Schulgen G (1991) Assessment of quality of life in clinical trials. Stat Med 10(12):1915\u20131930. https:\/\/doi.org\/10.1002\/sim.4780101207","journal-title":"Stat Med"},{"key":"5493_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR (2013) Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13. https:\/\/doi.org\/10.1186\/1756-8722-6-13","journal-title":"J Hematol Oncol"},{"issue":"7","key":"5493_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634\u20131646. https:\/\/doi.org\/10.1002\/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v","journal-title":"Cancer"},{"issue":"11","key":"5493_CR12","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.Ccr-03-0561","volume":"10","author":"XY Pei","year":"2004","unstructured":"Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10(11):3839\u20133852. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-03-0561","journal-title":"Clin Cancer Res"},{"issue":"19","key":"5493_CR13","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/jco.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113\u20133120. https:\/\/doi.org\/10.1200\/jco.2005.04.7779","journal-title":"J Clin Oncol"},{"key":"5493_CR14","unstructured":"NCI Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 10 Oct 2019"},{"issue":"4","key":"5493_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","volume":"94","author":"MW van der Poel","year":"2015","unstructured":"van der Poel MW, Oerlemans S, Schouten HC, van de Poll-Franse LV (2015) Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 94(4):651\u2013661. https:\/\/doi.org\/10.1007\/s00277-014-2264-0","journal-title":"Ann Hematol"},{"issue":"4","key":"5493_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2337\/diacare.26.4.1322-a","volume":"26","author":"RD Pathak","year":"2003","unstructured":"Pathak RD, Jayaraj K, Blonde L (2003) Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care 26(4):1322\u20131323. https:\/\/doi.org\/10.2337\/diacare.26.4.1322-a","journal-title":"Diabetes Care"},{"issue":"5","key":"5493_CR17","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"A Badros","year":"2007","unstructured":"Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110(5):1042\u20131049. https:\/\/doi.org\/10.1002\/cncr.22921","journal-title":"Cancer"},{"issue":"Suppl 1","key":"5493_CR18","first-page":"5","volume":"4","author":"S Kurtin","year":"2013","unstructured":"Kurtin S (2013) Relapsed or relapsed\/refractory multiple myeloma. J Adv Pract Oncol 4(Suppl 1):5\u201314","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"5493_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","volume":"88","author":"M Hjorth","year":"2012","unstructured":"Hjorth M, Hjertner O, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andreasson B, Billstrom R, Carlson K, Carlsson MS, Flogegard M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzen A, Swedin A (2012) Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 88(6):485\u2013496. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01775.x","journal-title":"Eur J Haematol"},{"key":"5493_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer 16:427. https:\/\/doi.org\/10.1186\/s12885-016-2410-2","journal-title":"BMC Cancer"},{"issue":"5","key":"5493_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97(5):416\u2013429. https:\/\/doi.org\/10.1111\/ejh.12790","journal-title":"Eur J Haematol"},{"issue":"10","key":"5493_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/jco.2002.08.131","volume":"20","author":"A \u00d6sterborg","year":"2002","unstructured":"\u00d6sterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20(10):2486\u20132494. https:\/\/doi.org\/10.1200\/jco.2002.08.131","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"5493_CR23","first-page":"S3","volume":"15","author":"ML Thomas","year":"1998","unstructured":"Thomas ML (1998) Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Med Oncol 15(Suppl 1):S3\u2013S7","journal-title":"Med Oncol"},{"key":"5493_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE (2014) Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes 12:35. https:\/\/doi.org\/10.1186\/1477-7525-12-35","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5493_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1365-2141.1997.222667.x","volume":"97","author":"F Wisl\u00d8ff","year":"1997","unstructured":"Wisl\u00d8ff F, Hjorth M (1997) Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Br J Haematol 97(1):29\u201337. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.222667.x","journal-title":"Br J Haematol"},{"issue":"6","key":"5493_CR26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/jco.2005.04.0824","volume":"4","author":"D Dubois","year":"2006","unstructured":"Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 4(6):976\u2013982. https:\/\/doi.org\/10.1200\/jco.2005.04.0824","journal-title":"J Clin Oncol"},{"issue":"7","key":"5493_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jclinepi.2006.10.006","volume":"60","author":"M Viala","year":"2007","unstructured":"Viala M, Bhakar AL, de la Loge C, van de Velde H, Esseltine D, Chang M, Dhawan R, Dubois D (2007) Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol 60(7):670\u2013679. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.10.006","journal-title":"J Clin Epidemiol"},{"issue":"17","key":"5493_CR28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"issue":"7","key":"5493_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos M-V, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, R\u00f6llig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"issue":"32","key":"5493_CR30","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, H\u00e1jek R, Rosi\u00f1ol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A (2016) Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol 34(32):3921\u20133930. https:\/\/doi.org\/10.1200\/JCO.2016.66.9648","journal-title":"J Clin Oncol"},{"issue":"4","key":"5493_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","volume":"143","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143(4):511\u2013519. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07378.x","journal-title":"Br J Haematol"},{"issue":"6","key":"5493_CR32","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel A-I, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, Miguel JS, Sonneveld P, Palumbo A (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98(6):980\u2013987. https:\/\/doi.org\/10.3324\/haematol.2012.075051","journal-title":"Haematologica"},{"issue":"9","key":"5493_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/17474086.2019.1645005","volume":"12","author":"P Niscola","year":"2019","unstructured":"Niscola P, Scaramucci L, Efficace F (2019) Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma. Expert Rev Hematol 12(9):703\u2013705. https:\/\/doi.org\/10.1080\/17474086.2019.1645005","journal-title":"Expert Rev Hematol"},{"issue":"24","key":"5493_CR34","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/jco.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32(24):2531\u20132540. https:\/\/doi.org\/10.1200\/jco.2014.55.1028","journal-title":"J Clin Oncol"},{"issue":"17","key":"5493_CR35","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/jco.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758\u20132765. https:\/\/doi.org\/10.1200\/jco.2008.20.8983","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05493-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:52:00Z","timestamp":1620694320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05493-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5493"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05493-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Teresa M. Zyczynski and Catherine Davis are employees of Bristol-Myers Squibb. The MD Anderson Symptom Inventory (MDASI) and its modules are copyrighted and licensed by The University of Texas MD Anderson Cancer Center and Charles S. Cleeland. Charles Cleeland and Xin Shelley Wang have a financial interest in the MDASI and its modules. The authors have no other financial conflict of interest to disclose. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}